Cucurbitacin E (Synonyms: α-Elaterin; α-Elaterine)

Name: Cucurbitacin E
Brand: MedChemExpress
SKU: HY-N0417
Rating: 5.0 (7 reviews)

Cat. No.: HY-N0417 Purity: 99.92%: FAQs
Data Sheet SDS COA Handling Instructions

Molarity Calculator

Cucurbitacin E is a natural compound which from Cucurbitaceae plants. Cucurbitacin E significantly suppresses the activity of the cyclin B1/CDC2 complex.

For research use only. We do not sell to patients.

Cucurbitacin E Chemical Structure

CAS No. : 18444-66-1

Size	Price	Stock	Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	USD 176	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	USD 176	In-stock	Estimated Time of Arrival: December 31
Solid
1 mg	USD 68	In-stock	Estimated Time of Arrival: December 31
5 mg	USD 144	In-stock	Estimated Time of Arrival: December 31
10 mg	USD 228	In-stock	Estimated Time of Arrival: December 31
50 mg		Get quote
100 mg		Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 7 publication(s) in Google Scholar

Other Forms of Cucurbitacin E:

6 Publications Citing Use of MCE Cucurbitacin E

: Cucurbitacin E purchased from MedChemExpress. Usage Cited in: Signal Transduct Target Ther. 2020 May 20;5(1):56. [Abstract]; Western Blot is performed to determine the protein levels of cyclin B1, Cdk1, and p-Drp1 Ser616. LMP1-positive cells are treated with or without cucurbitacin E (10 μM) for 24 h.

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All CDK Isoform Specific Products:

View All Isoforms

CDK1 CDK2 CDK3 CDK4 CDK5 CDK6 CDK7 CDK8 CDK9 CDK11 CDK12 CDK13 CDK14 CDK16 CDK19 CDC CLK Pho85

Biological Activity
Protocol
Purity & Documentation
References
Customer Review

Description

Cucurbitacin E is a natural compound which from Cucurbitaceae plants. Cucurbitacin E significantly suppresses the activity of the cyclin B1/CDC2 complex.

IC₅₀ & Target^[1]

cyclin B1/CDC2

Autophagy

Cellular Effect

Cell Line	Type	Value	Description	References
HeLa	IC₅₀	0.1 μM Compound: 12	Cytotoxicity against human HeLa cells after 24 hrs by MTT assay Cytotoxicity against human HeLa cells after 24 hrs by MTT assay	[PMID: 21459003]
HepG2	IC₅₀	15.25 μM Compound: 12	Cytotoxicity against human HepG2 cells after 24 hrs assessed as inhibition of cell viability by MTT assay Cytotoxicity against human HepG2 cells after 24 hrs assessed as inhibition of cell viability by MTT assay	[PMID: 21459003]
HepG2	EC₅₀	3.2 μM Compound: 12	Hepatoprotective activity in human HepG2 cells assessed as inhibition of CCl4-induced toxicity after 24 hrs by MTT assay Hepatoprotective activity in human HepG2 cells assessed as inhibition of CCl4-induced toxicity after 24 hrs by MTT assay	[PMID: 21459003]
HL-60	IC₅₀	18 nM Compound: 1	Cytotoxicity against human HL60 cells after 72 hrs by WST-8 assay Cytotoxicity against human HL60 cells after 72 hrs by WST-8 assay	[PMID: 20347305]
HSC-T6	EC₅₀	0.04 μM Compound: 12	Antiproliferative activity against serum-stimulated rat HSC-T6 cells after 24 hrs by MTT assay Antiproliferative activity against serum-stimulated rat HSC-T6 cells after 24 hrs by MTT assay	[PMID: 21459003]
HSC-T6	IC₅₀	2.03 μM Compound: 12	Cytotoxicity against rat HSC-T6 cell after 24 hrs by MTT assay Cytotoxicity against rat HSC-T6 cell after 24 hrs by MTT assay	[PMID: 21459003]
HT-1080	IC₅₀	40 nM Compound: 1	Cytotoxicity against human HT1080 cells after 72 hrs by WST-8 assay Cytotoxicity against human HT1080 cells after 72 hrs by WST-8 assay	[PMID: 20347305]
JY	IC₅₀	0.18 μM Compound: 1	Inhibition of LFA1 expressed in human JY cells interaction with ICAM1-IG expressed in human HeLa cell monolayer after 45 mins by cell adhesion assay Inhibition of LFA1 expressed in human JY cells interaction with ICAM1-IG expressed in human HeLa cell monolayer after 45 mins by cell adhesion assay	[PMID: 7852999]
MCF7	IC₅₀	0.055 μM Compound: 8	Cytotoxicity against human MCF7 cells assessed as growth inhibition after 72 hrs by MTS/PMS assay Cytotoxicity against human MCF7 cells assessed as growth inhibition after 72 hrs by MTS/PMS assay	[PMID: 25756299]
U-937	IC₅₀	16 nM Compound: 1	Cytotoxicity against human U937 cells after 72 hrs by WST-8 assay Cytotoxicity against human U937 cells after 72 hrs by WST-8 assay	[PMID: 20347305]

In Vitro

To explore the antitumor activity of Cucurbitacin E (CuE) against colorectal cancer (CRC) cells, an in vitro study is initiated in which each of the CRC cell lines is exposed to increasing doses of Cucurbitacin E (0, 2.5, 5, and 7.5?μM) over a period of 24?h. The proliferation of the Cucurbitacin E-treated cancer cells is then measured using the MTT method. Cucurbitacin E is shown to induce morphological changes in the primary colon cancer cells. Microscopic observation showed that following exposure to Cucurbitacin E (5?μM) between 6 and 24?h, the primary colon cancer cells underwent a remarkable change in morphology. Cucurbitacin E inhibits tumor growth by arresting the cell cycle in the G₂/M phase via GADD45γ gene expression and the blockage of cyclin B1/CDC2 complex in primary CRC cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

A high fat diet mice model of metabolic syndrome (HFD-MetS) is developed to assess the role of Cucurbitacin E (CuE) on body weight and fat tissue biology. Significant decrease in body weights of HFD-MetS mice treated with Cucurbitacin E (0.5mg/kg) are found as compared to HFD-MetS mice treated with vehicle alone. Cucurbitacin E treatment reduces all fat pads weights in HFD-MetS mice. 55% reduction is observed in total fat in mice, after treatment with Cucurbitacin E in comparison to HFD-MetS mice. Abdominal obesity is strongly associated with metabolic syndrome. Central obesity is reduced to 50% after Cucurbitacin E treatment as compared to HFD MetS mice, elucidating the effectiveness of Cucurbitacin E in targeting MetS^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Molecular Weight

556.69

Formula

C₃₂H₄₄O₈

CAS No.

18444-66-1

Appearance

Solid

Color

White to off-white

SMILES

O[C@H](C1)[C@@]([C@@](C)(O)C(/C=C/C(OC(C)=O)(C)C)=O)([H])[C@](C2)(C)[C@]1(C)[C@]3([H])CC=C4C(C)(C)C(C(O)=C[C@@]4([H])[C@]3(C)C2=O)=O

Structure Classification

Initial Source

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Solvent & Solubility

In Vitro:

DMSO : 50 mg/mL (89.82 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	1.7963 mL	8.9817 mL	17.9633 mL
5 mM	0.3593 mL	1.7963 mL	3.5927 mL
10 mM	0.1796 mL	0.8982 mL	1.7963 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 2.5 mg/mL (4.49 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (4.49 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.92%

Select Batch:

Data Sheet (281 KB) SDS (393 KB)

COA (252 KB) LCMS (141 KB)

Handling Instructions (2659 KB)

References

[1]. Hsu YC, et al. Therapeutic ROS targeting of GADD45γ in the induction of G2/M arrest in primary human colorectal cancer cell lines by cucurbitacin E. Cell Death Dis. 2014 Apr 24;5:e1198. [Content Brief]

[2]. Murtaza M, et al. Cucurbitacin E reduces obesity and related metabolic dysfunction in mice by targeting JAK-STAT5 signaling pathway. PLoS One. 2017 Jun 9;12(6):e0178910. [Content Brief]

Cell Assay ^[1]	The colorectal cancer (CRC) cells are seeded into 96-well culture plates at 5000 cells/well. The cells are treated with 0, 2.5, 5, and 7.5 μM Cucurbitacin E for 1-3 days. MTT dye (1 mg/mL) is added to each well for at least 4 h of treatment. The reaction is stopped by the addition of DMSO, and optical density is measured at 540 nm on a multi-well plate reader. Background absorbance of the medium in the absence of cells is subtracted. All samples are assayed in triplicate, and the mean for each experiment is calculated. Results are expressed as a percentage of control, which is considered as 100%. Each assay is carried out in triplicate, and the results are expressed as the mean^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Administration ^[2]	Mice^[2] C57BL/6 male mice are used. The mice are designated as metabolic syndrome mice (HFD-MetS-mice). Briefly, the mice are randomly assigned into two groups according to their diet for 8 weeks (n = 10-12): high fat diet group (HFD) (60% fat, 20% carbohydrate, 20% protein) or the matched low fat, standard diet group (SD) (10% fat, 70% carbohydrate, 20% protein). After eight weeks on high fat diet, the mice with significant obese phenotype and fasting blood glucose levels ≥126 mg/dL are considered MetS mice. The MetS mice are continued on the HFD throughout the study. The MetS mice are then randomly divided into three additional groups, according to the treatment administered by oral gavage for 10 weeks (n=10-12): a low dose 0.25 mg/kg/day of Cucurbitacin E designated as HFD+Cucurbitacin E (L) or high dose 0.5 mg/kg/day of Cucurbitacin E, designated as HFD+Cucurbitacin E (H) or 50 mg/kg/day Orlistat (HFD+Orlistat). Animals on SD are administered 0.5% CMC by oral gavage^[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
References	[1]. Hsu YC, et al. Therapeutic ROS targeting of GADD45γ in the induction of G2/M arrest in primary human colorectal cancer cell lines by cucurbitacin E. Cell Death Dis. 2014 Apr 24;5:e1198. [Content Brief] [2]. Murtaza M, et al. Cucurbitacin E reduces obesity and related metabolic dysfunction in mice by targeting JAK-STAT5 signaling pathway. PLoS One. 2017 Jun 9;12(6):e0178910. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	1.7963 mL	8.9817 mL	17.9633 mL	44.9083 mL
	5 mM	0.3593 mL	1.7963 mL	3.5927 mL	8.9817 mL
	10 mM	0.1796 mL	0.8982 mL	1.7963 mL	4.4908 mL
	15 mM	0.1198 mL	0.5988 mL	1.1976 mL	2.9939 mL
	20 mM	0.0898 mL	0.4491 mL	0.8982 mL	2.2454 mL
	25 mM	0.0719 mL	0.3593 mL	0.7185 mL	1.7963 mL
	30 mM	0.0599 mL	0.2994 mL	0.5988 mL	1.4969 mL
	40 mM	0.0449 mL	0.2245 mL	0.4491 mL	1.1227 mL
	50 mM	0.0359 mL	0.1796 mL	0.3593 mL	0.8982 mL
	60 mM	0.0299 mL	0.1497 mL	0.2994 mL	0.7485 mL
	80 mM	0.0225 mL	0.1123 mL	0.2245 mL	0.5614 mL

Cucurbitacin E Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Cucurbitacin E18444-66-1α-Elaterin α-ElaterineCDKAutophagyCyclin dependent kinaseInhibitorinhibitorinhibit

Please select a local distributor ナミキ商事株式会社コスモ・バイオ株式会社
Product Name			Salutation
Applicant Name *			Email Address *
Phone Number *			Organization Name *
Department *			Requested quantity *
Country or Region *
Remarks

Product Name			Lot #
Applicant Name *			Email Address *
Phone Number			Department *
Organization Name *			Country or Region *
Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

Cucurbitacin E (Synonyms: α-Elaterin; α-Elaterine)

Customer Review

Other Forms of Cucurbitacin E:

Cucurbitacin E Related Antibodies

6 Publications Citing Use of MCE Cucurbitacin E

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All CDK Isoform Specific Products:

Biological Activity

Protocol

Purity & Documentation

References

Customer Review

Cucurbitacin E Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Cucurbitacin E Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report